Withdrawal Of Atrioventricular Nodal Blocking Agents in Patients Receiving Mavacamten: A Retrospective Single-Center Experience in A Predominantly Asian-American Cohort

Withdrawal Of Atrioventricular Nodal Blocking Agents in Patients Receiving Mavacamten: A Retrospective Single-Center Experience in A Predominantly Asian-American Cohort

•Atrioventricular nodal blockers can be safely discontinued after starting mavacamten.•Mavacamten is effective in Asian-American cohorts.•Symptom reduction often occurs at the first visit after initiation.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2024-04, Vol.216, p.63-65
Hauptverfasser: Benavente, Kevin, Moreno, Jesus Pino, Banerjee, Dipanjan
Format: Artikel
Sprache:eng
Schlagworte:
Asian Americans
Atrioventricular Block
AVN blocking agents
Benzylamines
Cardiac arrhythmia
Cardiomyopathy, Hypertrophic
Ejection fraction
Hospitalization
Humans
hypertrophic cardiomyopathy
mavacamten
myosin
Pacific Islander people
Patients
Retrospective Studies
Uracil - analogs & derivatives
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Atrioventricular nodal blockers can be safely discontinued after starting mavacamten.•Mavacamten is effective in Asian-American cohorts.•Symptom reduction often occurs at the first visit after initiation.
ISSN:0002-9149
1879-1913
1879-1913
DOI:10.1016/j.amjcard.2023.11.027